Last reviewed · How we verify
NCT04807881
Phase Ib Clinical Study of Keynatinib
Phase 1 trial testing Keynatinib in Lymphoma, B-Cell in 75 participants. Currently enrolling.
10 October 2027
Quick facts
| Lead sponsor | Medolution Ltd. |
|---|---|
| Phase | Phase 1 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 75 |
| Start date | 24 September 2020 |
| Primary completion | 10 October 2027 |
| Estimated completion | 10 April 2028 |
| Sites | 4 locations across China |
Drugs / interventions tested
- Keynatinib — full drug profile →
Conditions studied
- Lymphoma, B-Cell — all drugs for Lymphoma, B-Cell →
Sponsor
Medolution Ltd. — full company profile →
Who can join
18 and older, any sex, with Lymphoma, B-Cell. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The purpose of this study is to evaluate the efficacy, safety, PK characteristics in subjects with relapsed/refractory B-cell lymphoma. Furthermore, the relationship between the exposure level of Keynatinib and its efficacy and safety, the penetration rate of keynatinib in the Blood-Brain Barrier (BBB) and its PK characteristics in cerebrospinal fluid in R/R-PCNSL patients, the relationship between the BTK receptor occupancy rate and the efficacy are also evaluated.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Chronic Lymphocytic Leukemia: Novel Therapeutic Targets Under Investigation.
Nayyar M, Menezes RCB, Ailawadhi S, Parrondo RD. · · 2025 · cited 2× · PMID 40723181 · DOI 10.3390/cancers17142298
Verify or expand the search:
- PubMed search for NCT04807881
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Keynatinib
Trials testing the same drug.
- NCT04824079 — Keynatinib in Treated Patients With NSCLC and Brain Metastases · Phase 2 · completed
Other recruiting trials for Lymphoma, B-Cell
Currently open trials in the same condition.
- NCT06850285 — CD30 CAR-T in the Treatment of CD30 Positive Relapsed/Refractory Lymphoma · NA · recruiting
- NCT06954805 — Defining ctDNA Metrics in Posttransplant Lymphoproliferative Disorder (PTLD) · Phase 2 · recruiting
- NCT06609304 — Axicabtagene Ciloleucel for Consolidation After First-line Treatment of High-risk Large B-cell Lymphoma · Phase 4 · recruiting
- NCT06866873 — CD-19 CAR-T Cell for Pediatric ALL or Lymphoma · NA · recruiting
- NCT06381830 — Clinical Study of CAR-T Cell Therapy Following ASCT for R/R B-cell Non-Hodgkin's Lymphoma · Phase 2 · recruiting
Other Medolution Ltd. trials
Trials by the same sponsor.
- NCT04824079 — Keynatinib in Treated Patients With NSCLC and Brain Metastases · Phase 2 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04807881 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Medolution Ltd.
- Last refreshed: 22 January 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04807881.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing